<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nurexone Biologic Inc. — News on 6ix</title>
<link>https://6ix.com/company/nurexone-biologic-inc</link>
<description>Latest news and press releases for Nurexone Biologic Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:03:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nurexone-biologic-inc" rel="self" type="application/rss+xml" />
<item>
<title>Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/australian-patent-granted-to-nurexone-covering-stem-cell-derived-exosome-production</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/australian-patent-granted-to-nurexone-covering-stem-cell-derived-exosome-production</guid>
<pubDate>Mon, 27 Apr 2026 20:03:00 GMT</pubDate>
<description>Sheba medical center researcher to present NurExone’s exosome optic nerve regeneration work at ISCEV@DenverTORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, is pleased to announce that a patent covering the “Production of extracellular vesicles from stem cells” has been gra</description>
</item>
<item>
<title>NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologic-inc-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologic-inc-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 16 Apr 2026 13:15:00 GMT</pubDate>
<description>TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system (“CNS”) injuries is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2025. The Company’s lead program, ExoPTEN, is being developed for acute spinal cord i</description>
</item>
<item>
<title>NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-to-participate-in-water-tower-research-insights-conference-on-april-14-2026</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-to-participate-in-water-tower-research-insights-conference-on-april-14-2026</guid>
<pubDate>Fri, 10 Apr 2026 20:03:00 GMT</pubDate>
<description>Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (T...</description>
</item>
<item>
<title>NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologics-us-subsidiary-exo-top-and-florida-based-bioxtek-sign-strategic-loi-for-exosome-manufacturing-and-commercialization</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologics-us-subsidiary-exo-top-and-florida-based-bioxtek-sign-strategic-loi-for-exosome-manufacturing-and-commercialization</guid>
<pubDate>Tue, 07 Apr 2026 13:18:00 GMT</pubDate>
<description>TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) --...</description>
</item>
<item>
<title>NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologics-us-subsidiary-exo-top-and-florida-based-bioxtek-sign-strategic-loi-for-exosome-manufacturing-and-commercialization-1</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologics-us-subsidiary-exo-top-and-florida-based-bioxtek-sign-strategic-loi-for-exosome-manufacturing-and-commercialization-1</guid>
<pubDate>Tue, 07 Apr 2026 13:18:00 GMT</pubDate>
<description>TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) and BioXtek Inc. (“BioXtek”) today announced that Exo-Top Inc., NurExone’s wholly owned U.S. subsidiary, (“Exo-Top” and together, with BioXtek, the “Parties”) has entered into a non-binding letter of intent (the “LOI”) with BioXtek, a Florida-based company, to explore a strategic partnership in the field of re</description>
</item>
<item>
<title>NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-receives-first-place-in-healthcare-at-bold-awards-vii-and-engages-investor-brand-network-to-support-awareness-strategy-6</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-receives-first-place-in-healthcare-at-bold-awards-vii-and-engages-investor-brand-network-to-support-awareness-strategy-6</guid>
<pubDate>Wed, 01 Apr 2026 13:17:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) ...</description>
</item>
<item>
<title>NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-strengthens-us-manufacturing-strategy-through-exo-top-sublicense-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-strengthens-us-manufacturing-strategy-through-exo-top-sublicense-agreement</guid>
<pubDate>Thu, 26 Mar 2026 20:03:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)...</description>
</item>
<item>
<title>NurExone Announces Corporate Updates</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-announces-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-announces-corporate-updates</guid>
<pubDate>Wed, 11 Mar 2026 12:28:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) ...</description>
</item>
<item>
<title>NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-to-showcase-its-regenerative-medicine-platform-at-nanoil2026-and-advanced-therapies-congress-in-march-2026-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-to-showcase-its-regenerative-medicine-platform-at-nanoil2026-and-advanced-therapies-congress-in-march-2026-and-provides-corporate-update</guid>
<pubDate>Fri, 27 Feb 2026 21:03:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026. Dr. Lior Shaltiel, PhD, Chief Executive Officer of NurExone, commented, “Engaging with scientific, industry, and investor audiences is a core part of our strategy, and March i</description>
</item>
<item>
<title>NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologic-advances-manufacturing-regulatory-210300867</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologic-advances-manufacturing-regulatory-210300867</guid>
<pubDate>Tue, 10 Feb 2026 21:03:00 GMT</pubDate>
<description>Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced results from an independent proteomic analysis conducted at the Technion - Israel Institute of Technology. which evaluated multiple production batches of NurExone's exosomes. The results support the...</description>
</item>
<item>
<title>NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-appoints-eyal-gabbai-board-210300888</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-appoints-eyal-gabbai-board-210300888</guid>
<pubDate>Fri, 30 Jan 2026 21:03:00 GMT</pubDate>
<description>Chairman of Meuhedet, Israel’s third-largest health fundTORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced changes to its board of directors (the “Board”). Effective today, Mr. Eyal Gabbai has been appointed to the Board replacing Dr. Gadi Riesenfeld, who has resigned from the Board. Dr. Riesenfeld will continue to support NurExone as a member of the Company’s Scientific Advisory</description>
</item>
<item>
<title>NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-reports-anti-inflammatory-activity-of-its-exosomes-in-lab-analysis</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-reports-anti-inflammatory-activity-of-its-exosomes-in-lab-analysis</guid>
<pubDate>Fri, 19 Dec 2025 21:04:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (...</description>
</item>
<item>
<title>NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-plans-small-scale-of-exopten-clinical-manufacturing-in-preparation-for-future-first-in-human-use-pathways</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-plans-small-scale-of-exopten-clinical-manufacturing-in-preparation-for-future-first-in-human-use-pathways</guid>
<pubDate>Fri, 12 Dec 2025 21:04:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (...</description>
</item>
<item>
<title>NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologic-inc-announces-third-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-biologic-inc-announces-third-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Fri, 28 Nov 2025 14:15:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NR...</description>
</item>
<item>
<title>NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-secures-over-cdollar318-million-through-accelerated-warrant-exercises</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-secures-over-cdollar318-million-through-accelerated-warrant-exercises</guid>
<pubDate>Wed, 12 Nov 2025 21:02:40 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NR...</description>
</item>
<item>
<title>NurExone Accepted into ARMI's BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-accepted-into-armis-biofab-startup-lab-strengthening-us-position-in-regenerative-manufacturing</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-accepted-into-armis-biofab-startup-lab-strengthening-us-position-in-regenerative-manufacturing</guid>
<pubDate>Mon, 03 Nov 2025 21:04:45 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (...</description>
</item>
<item>
<title>NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-accepted-armi-biofab-startup-210400260</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-accepted-armi-biofab-startup-210400260</guid>
<pubDate>Mon, 03 Nov 2025 21:04:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) announced today that it has been accepted to the BioFab Startup Lab, part of the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA program. The federally-supported program, launched through a grant from the U.S. Economic Development Administration, helps early-stage biotechnology companies accelerate the translation of regene</description>
</item>
<item>
<title>NurExone Invited Presenter at Precision EV Forum in Cambridge, UK</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-invited-presenter-at-precision-ev-forum-in-cambridge-uk</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-invited-presenter-at-precision-ev-forum-in-cambridge-uk</guid>
<pubDate>Tue, 21 Oct 2025 20:04:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (...</description>
</item>
<item>
<title>NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model</guid>
<pubDate>Wed, 08 Oct 2025 12:30:00 GMT</pubDate>
<description>TORONTO&#xA0;and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: N...</description>
</item>
<item>
<title>NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana</title>
<link>https://6ix.com/company/nurexone-biologic-inc/news/nurexone-planning-to-establish-first-us-commercial-manufacturing-facility-in-indiana</link>
<guid isPermaLink="true">https://6ix.com/company/nurexone-biologic-inc/news/nurexone-planning-to-establish-first-us-commercial-manufacturing-facility-in-indiana</guid>
<pubDate>Tue, 16 Sep 2025 20:15:00 GMT</pubDate>
<description>TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic ...</description>
</item>
</channel>
</rss>